Browsing by Author "Cinar E."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Cystoid Macular Edema
    (Lippincott Williams and Wilkins, 2018) Mansour A.M.; Sheheitli H.; Kucukerdonmez C.; Sisk R.A.; Moura R.; Moschos M.M.; Lima L.H.; Al-Shaar L.; Arevalo J.F.; Maia M.; Foster R.E.; Kayikcioglu O.; Kozak I.; Kurup S.; Zegarra H.; Gallego-Pinazo R.; Hamam R.N.; Bejjani R.A.; Cinar E.; Erakgün E.T.; Kimura A.; Teixeira A.
    Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (m) decreased from 506 ± 288 m to 311.7 ± 71.6 m (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage. © Ophthalmic Communications Society, Inc.
  • No Thumbnail Available
    Item
    Anti-acetylcholinesterase, antiprotozoal and cytotoxic activities of some Turkish marine algae
    (Parlar Scientific Publications, 2019) Cinar E.; Taskin E.; Tasdemir D.; Ozkale E.; Grienke U.; Firsova D.
    The crude (MeOH:CHCl3) and n-hexane-soluble extracts from four brown algae (Phaeophyceae) [Petalonia fascia, Cystoseira crinita, Cystoseira foeniculacea, and Halopteris scoparia], one red alga (Rhodophyta) [Jania rubens] and three green algae (Chlorophyta) [Chaetomorpha aerea, Codium fragile subsp. fragile, and Ulva compressa] from Turkish coasts (Izmir Bay, Ayvalik and Çanakkale) were assessed in vitro for their acetylcholinesterase (AChE) inhibitory activities at 200, 150, 50, 20 μg/mL test concentration with Ellman's method. The crude extract of P. fascia possessed the highest inhibition (IC5 0 value of 19,22±10,47 μg/mL) against AChE. Galanthamine HBr was used as standard drug that gave against AChE enzyme IC5 0 of 3.44±1.14 μM. In the second stage, the crude, hexane-soluble, chloroform-soluble and water-methanol soluble extracts of the marine algae were observed in vitro against parasitic protozoa (Plasmodium falciparum, Trypanosoma brucei brucei, Trypanosoma cruzi ve Leishmania infantum). According to results, the most potent protozoal activities were shown by the Khex of C. crinita (IC5 0 value of 10,62 μg/ml), followed by the Khex of C. fragile subsp. fragile (IC50 value of 11,89 μg/ml). The hekzan-soluble (Khex) and chloroform-soluble (KCH) extracts gave the best results. The marine algae were also tested on MRC-5 cells (human fibroblasts) for by controlling tamoxifen. The extracts of H. scoparia, C. aerea ve C. fragile subsp. fragile showed toxicity. © by PSP